4.7 Article

Infections and Association With Different Intensity of Chemotherapy in Children With Acute Myeloid Leukemia

Journal

CANCER
Volume 115, Issue 5, Pages 1100-1108

Publisher

WILEY
DOI: 10.1002/cncr.24107

Keywords

infections; children; acute myeloid leukemia; stem cell transplantation

Categories

Funding

  1. NCI NIH HHS [U10 CA098543-06, U10 CA098543, U10 CA098413, U10 CA095861, U10 CA098413-06, U10 CA095861-08, U10 CA095861-06] Funding Source: Medline

Ask authors/readers for more resources

BACKGROUND: The objectives were to compare infections during different intensities of therapy in children with acute myeloid leukemia (AML). METHODS: Subjects were children enrolled in Children's Cancer Group 2891 with AML. In phase 1 (induction), patients were randomized to intensive or standard timing. In phase 2 (consolidation), those with a family donor were allocated allogeneic stem cell transplantation (SCT); the remainder were randomized to autologous SCT or chemotherapy. This report compares infections between different treatments on an intent-to-treat basis. RESULTS: During phase 1, intensive timing was associated with more bacterial (57.7% vs 39.4%; P < .001), fungal (27.4% vs 9.9%; P < .001), and viral (14.0% vs 3.9%; P < .001) infections compared with standard timing. During phase 2, chemotherapy was associated with more bacterial (56.5% vs 40.1%; P = .005), but similar fungal (9.5% vs 6.1%; P = 1.000) and viral (4.2% vs 12.9%; P = .728) infections compared with allogeneic SCT. No differences between chemotherapy and autologous SCT infections were seen. Fatal infections were more common during intensive compared with standard timing induction (5.5% vs 0.9%; P = .004). Infectious deaths were similar between chemotherapy, autologous SCT, and allogeneic SCT. CONCLUSIONS: Prevalence of infection varies depending on the intensity and type of treatment. This information sheds insight into the mechanisms behind susceptibility and outcome of infections in pediatric AML. Cancer 2009;115:1100-8. (c) 2009 American Cancer Society.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available